

Edgar Filing: ANTARES PHARMA INC - Form 8-K

ANTARES PHARMA INC
Form 8-K
June 30, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 Or 15(D) of The
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 27, 2003

ANTARES PHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

| | | |
|---|-----------------------------|---|
| Minnesota | 0-20945 | 41-1350192 |
| ----- | ----- | ----- |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

| | |
|---|------------|
| 707 Eagleview Boulevard, Suite 414, Exton, PA | 19341 |
| ----- | ----- |
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code: (610) 458-6200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events and Required FD Disclosure.

On June 30, 2003, Antares Pharma, Inc. (the "Company") announced that on June 27 2003, the Listing Qualifications arm of The Nasdaq Stock Market, Inc. had determined to delist the Company's shares of common stock from trading on The Nasdaq SmallCap Market effective with the open of business on Tuesday, July 1, 2003. The Company's common stock will be immediately eligible for quotation on the OTC Bulletin Board effective with the open of business on Tuesday, July 1, 2003, provided that a market maker enters a quote for such securities on the first day of eligibility. The Company's common stock will trade under the same ticker symbol: ANTR.

A copy of the press release issued by the Company on June 30, 2003 is attached hereto as Exhibit 99.1

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

Edgar Filing: ANTARES PHARMA INC - Form 8-K

(c) Exhibits.

99.1 Press Release dated June 30, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 30, 2003

ANTARES PHARMA, INC.

By /s/ Lawrence M. Christian

Lawrence M. Christian
Chief Financial Officer

EXHIBIT INDEX

99.1 Press Release dated June 30, 2003.